FDA Calls for Review of Opioids Policy, Announces Action Plan

As part of a broad national campaign to address opioid abuse, dependence, and overdose, Food and Drug Administration (FDA) Deputy Commissioner for Medical Products and Tobacco, Dr Robert Califf, along with other FDA leaders, developed a comprehensive action plan to reassess the agency’s approach to opioid medications.

Read more

Substantial Decline Seen in Number of Hydrocodone Combination Product Prescriptions Dispensed From US Pharmacies

In the year after the United States Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products from Schedule III to the more restrictive Schedule II because of the high potential for abuse, 26.3 million fewer hydrocodone combination product prescriptions were written and 1.1 billion fewer hydrocodone combination product tablets were dispensed, indicates a new study.

Read more

The AWARxE prescription drug safety program is brought to you by the NABP FoundationTM

Copyright © 2016 National Association of Boards of Pharmacy® (NABP®).